Anti-LONP1 [LON20/H1]
Invented by Helen Turley from University of Oxford
Invented at University of Oxford
- Datasheet
- References (2)
- Inventor Info
Info
Catalogue Number | 152791 |
Applications | ELISA IHC WB |
Antigen/Gene or Protein Targets | Human LON protease |
Synonyms | hLON, hLON ATP dependent protease, LON, LONP1, lon peptidase 1, mitochondrial, LON protease, Lon protease homolog, Lon protease like protein, Lon protease-like protein |
Reactivity | Human |
Relevance | ATP-dependent serine protease that mediates the selective degradation of misfolded, unassembled or oxidatively damaged polypeptides as well as certain short-lived regulatory proteins in the mitochondrial matrix. May also have a chaperone function in the assembly of inner membrane protein complexes. Participates in the regulation of mitochondrial gene expression and in the maintenance of the integrity of the mitochondrial genome. Binds to mitochondrial promoters and RNA in a single-stranded, site-specific, and strand-specific manner. |
Host | Mouse |
Immunogen | KLH-peptide conjugate - N-CEKDDKDAIEEKFRERLKE-C |
Positive Control | U87 cells |
Subclass | IgG |
Molecular Weight (kDa) | 106 |
Recommended Growing Conditions | RPMI 10% FCS plus HAT essential |
Research Area | Cancer, Epigenetics & Nuclear Signalling, Metabolism |
References: 2 entries
Cameron Edward Snell PhD thesis, (2013). Mitochondrial modulators of hypoxia-related pathways in tumours. DPhil. University of Oxford.
IHC WB
Snell et al., 2016. Targeting the mitochondrial Lon protease reduces aerobic glycolysis and HIF-1a stabilisation in tumour cells. Submitted for publication.
Add a reference
References: 2 entries
Cameron Edward Snell PhD thesis, (2013). Mitochondrial modulators of hypoxia-related pathways in tumours. DPhil. University of Oxford.
IHC WB
Snell et al., 2016. Targeting the mitochondrial Lon protease reduces aerobic glycolysis and HIF-1a stabilisation in tumour cells. Submitted for publication.
Add a reference